These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22468086)

  • 1. High-dose infliximab for treatment of pediatric ulcerative colitis: a survey of clinical practice.
    Nattiv R; Wojcicki JM; Garnett EA; Gupta N; Heyman MB
    World J Gastroenterol; 2012 Mar; 18(11):1229-34. PubMed ID: 22468086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.
    Yamada S; Yoshino T; Matsuura M; Minami N; Toyonaga T; Honzawa Y; Tsuji Y; Nakase H
    BMC Gastroenterol; 2014 Apr; 14():80. PubMed ID: 24758588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of pediatric ulcerative colitis after infliximab failure: A multicenter registry-based cohort study.
    Nambu R; Kudo T; Tachibana N; Shimizu H; Mizuochi T; Kato S; Inoue M; Kumagai H; Ishige T; Kunisaki R; Noguchi A; Yodoshi T; Hagiwara SI; Nishimata S; Kakuta F; Saito T; Iwama I; Hirano Y; Shimizu T; Arai K;
    J Gastroenterol Hepatol; 2024 Feb; 39(2):312-318. PubMed ID: 38058020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of disease may predict response to infliximab in pediatric ulcerative colitis.
    Mir SA; Nagy-Szakal D; Smith EO; Gilger MA; Kellermayer R
    J Clin Gastroenterol; 2014 Mar; 48(3):248-52. PubMed ID: 24129407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.
    Halpin SJ; Hamlin PJ; Greer DP; Warren L; Ford AC
    World J Gastroenterol; 2013 Feb; 19(7):1091-7. PubMed ID: 23467174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
    Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
    United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of early response to infliximab in patients with ulcerative colitis.
    Ferrante M; Vermeire S; Katsanos KH; Noman M; Van Assche G; Schnitzler F; Arijs I; De Hertogh G; Hoffman I; Geboes JK; Rutgeerts P
    Inflamm Bowel Dis; 2007 Feb; 13(2):123-8. PubMed ID: 17206703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation].
    Knyazev OV; Shkurko TV; Kagramanova AV; Lishchinskaya AA; Zvyaglova MY; Korneeva IA; Babayan AF; Parfenov AI
    Ter Arkh; 2019 Aug; 91(8):41-46. PubMed ID: 32598753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
    Vahabnezhad E; Rabizadeh S; Dubinsky MC
    Inflamm Bowel Dis; 2014 Apr; 20(4):606-13. PubMed ID: 24552827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
    Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
    Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H; Arai K; Kagimoto S; Kunisaki R; Hida N; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
    BMC Pediatr; 2019 Oct; 19(1):351. PubMed ID: 31607268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
    Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
    Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
    Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
    Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?
    Rizzo G; Pugliese D; Armuzzi A; Coco C
    World J Gastroenterol; 2014 May; 20(17):4839-45. PubMed ID: 24803795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.